Table 1 (abstract P457). Results of SARS-CoV-2 tests and outcomes of children and adolescents with critical disease related to SARS-CoV-2 (severe COVID-19 and MIS-C)
From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
| Â | Severe COVID-19 (n=127) | MIS-C (n=65) | All patients (n=192) | p value |
|---|---|---|---|---|
SARS-CoV-2 tests | ||||
 SARS-CoV-2 RT-PCR positive | 56/75 (74.7) | 21/61 (34.4) | 77/136 (56.2) | 0.013 |
 SARS-CoV-2 Antigen positive | 60/83 (72.3) | 28/52 (53.8) | 88/135 (65.2) | 0.32 |
 SARS-CoV-2 ELISA IgG positive | 4/47 (8.5) | 16 /21(76.2) | 20/68 (29.4) | <0.001 |
 SARS-CoV-2 ELISA IgM positive | 11/47 (23.4) | 4 /21 (17.4) | 15/68 (22.1) | 0.05 |
Outcomes | ||||
 Length of PICU stay, in days | 3 (2-9) | 6 (3-12) | 5 (2-10.5) | <0.001 |
 Length of hospital stay, in days | 14 (10-20) | 15 (10-19) | 14 (10-20) | 0.15 |
 Deaths | 19 (15) | 16 (24.6) | 35 (18.2) | 0.13 |